AU2018243691B2 - Heterocyclic compound - Google Patents
Heterocyclic compound Download PDFInfo
- Publication number
- AU2018243691B2 AU2018243691B2 AU2018243691A AU2018243691A AU2018243691B2 AU 2018243691 B2 AU2018243691 B2 AU 2018243691B2 AU 2018243691 A AU2018243691 A AU 2018243691A AU 2018243691 A AU2018243691 A AU 2018243691A AU 2018243691 B2 AU2018243691 B2 AU 2018243691B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- substituted
- alkyl
- substituents selected
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762476970P | 2017-03-27 | 2017-03-27 | |
| US62/476,970 | 2017-03-27 | ||
| PCT/US2018/024043 WO2018183112A1 (en) | 2017-03-27 | 2018-03-23 | Heterocyclic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018243691A1 AU2018243691A1 (en) | 2019-10-24 |
| AU2018243691B2 true AU2018243691B2 (en) | 2022-05-12 |
Family
ID=63671942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018243691A Active AU2018243691B2 (en) | 2017-03-27 | 2018-03-23 | Heterocyclic compound |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10543212B2 (enExample) |
| EP (1) | EP3600327A4 (enExample) |
| JP (1) | JP7249950B2 (enExample) |
| KR (1) | KR102638678B1 (enExample) |
| CN (1) | CN110799190B (enExample) |
| AU (1) | AU2018243691B2 (enExample) |
| CA (1) | CA3058182A1 (enExample) |
| TW (1) | TWI789381B (enExample) |
| WO (1) | WO2018183112A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102638678B1 (ko) | 2017-03-27 | 2024-02-19 | 카듀리온 파마슈티칼스, 인크. | 헤테로시클릭 화합물 |
| BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
| WO2020068846A1 (en) * | 2018-09-25 | 2020-04-02 | Heterocyclic Compound | Heterocyclic compound |
| KR20210082454A (ko) * | 2018-09-25 | 2021-07-05 | 카듀리온 파마슈티칼스, 인크. | 아미노피리미딘 화합물 |
| AU2019413360B2 (en) | 2018-12-28 | 2025-05-22 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| KR20250155067A (ko) * | 2019-10-25 | 2025-10-29 | 길리애드 사이언시즈, 인코포레이티드 | Glp-1r 조절 화합물 |
| PT4097097T (pt) | 2020-01-29 | 2025-03-28 | Gilead Sciences Inc | Compostos moduladores de glp-1r |
| KR102563111B1 (ko) * | 2020-03-18 | 2023-08-04 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| NZ792968A (en) * | 2020-03-18 | 2025-08-29 | Lg Chemical Ltd | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| TW202229273A (zh) | 2020-09-28 | 2022-08-01 | 美商卡都瑞恩醫藥有限責任公司 | 稠合雜芳基化合物及其作為CaMKII抑制劑之用途 |
| WO2022109182A1 (en) | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| JP2024514259A (ja) * | 2021-04-08 | 2024-03-29 | エルジー・ケム・リミテッド | Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法 |
| JP7600433B2 (ja) | 2021-04-21 | 2024-12-16 | ギリアード サイエンシーズ， インコーポレイテッド | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
| JP7777891B2 (ja) | 2021-12-29 | 2025-12-01 | サイ セラピューティクス インコーポレイテッド | モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害 |
| WO2023130050A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain |
| CN114621312B (zh) * | 2022-03-24 | 2022-11-15 | 陕西师范大学 | 一种寡肽烷基侧链的选择性修饰方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002011724A2 (en) * | 2000-08-08 | 2002-02-14 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective 2-pyridinamine compositions and related methods |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004523474A (ja) | 2000-09-20 | 2004-08-05 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | チロシンキナーゼモジュレーターとしてのピラジン誘導体 |
| WO2005012262A1 (en) * | 2003-07-30 | 2005-02-10 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| US20070027321A1 (en) | 2003-09-02 | 2007-02-01 | Kamenecka Theodore M | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
| US7776857B2 (en) * | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| AR073760A1 (es) * | 2008-10-03 | 2010-12-01 | Astrazeneca Ab | Derivados heterociclicos y metodos de uso de los mismos |
| GB0821307D0 (en) * | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2638018A1 (en) * | 2010-11-09 | 2013-09-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| TWI596089B (zh) | 2012-04-17 | 2017-08-21 | 富士軟片股份有限公司 | 含氮雜環化合物或其鹽 |
| KR102638678B1 (ko) * | 2017-03-27 | 2024-02-19 | 카듀리온 파마슈티칼스, 인크. | 헤테로시클릭 화합물 |
-
2018
- 2018-03-23 KR KR1020197031604A patent/KR102638678B1/ko active Active
- 2018-03-23 EP EP18777887.3A patent/EP3600327A4/en active Pending
- 2018-03-23 WO PCT/US2018/024043 patent/WO2018183112A1/en not_active Ceased
- 2018-03-23 AU AU2018243691A patent/AU2018243691B2/en active Active
- 2018-03-23 CA CA3058182A patent/CA3058182A1/en active Pending
- 2018-03-23 US US15/933,889 patent/US10543212B2/en active Active
- 2018-03-23 JP JP2019553090A patent/JP7249950B2/ja active Active
- 2018-03-23 CN CN201880021628.6A patent/CN110799190B/zh active Active
- 2018-03-26 TW TW107110319A patent/TWI789381B/zh active
-
2020
- 2020-01-27 US US16/773,730 patent/US11197858B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002011724A2 (en) * | 2000-08-08 | 2002-02-14 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective 2-pyridinamine compositions and related methods |
Also Published As
| Publication number | Publication date |
|---|---|
| US11197858B2 (en) | 2021-12-14 |
| JP7249950B2 (ja) | 2023-03-31 |
| US20200230137A1 (en) | 2020-07-23 |
| JP2020515575A (ja) | 2020-05-28 |
| EP3600327A1 (en) | 2020-02-05 |
| KR20200027917A (ko) | 2020-03-13 |
| WO2018183112A1 (en) | 2018-10-04 |
| US20180280389A1 (en) | 2018-10-04 |
| TW201904959A (zh) | 2019-02-01 |
| TWI789381B (zh) | 2023-01-11 |
| US10543212B2 (en) | 2020-01-28 |
| AU2018243691A1 (en) | 2019-10-24 |
| EP3600327A4 (en) | 2020-10-28 |
| CN110799190B (zh) | 2024-04-19 |
| CN110799190A (zh) | 2020-02-14 |
| KR102638678B1 (ko) | 2024-02-19 |
| CA3058182A1 (en) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018243691B2 (en) | Heterocyclic compound | |
| AU2015250610B2 (en) | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | |
| KR20210014108A (ko) | Parp7 억제제로서의 피리다지논 | |
| EA016204B1 (ru) | Производные триазолпиразинов, применимые в качестве противораковых агентов | |
| US12435063B2 (en) | Nitrogen containing heterocycles as CDK12 inhibitors | |
| WO2017003995A1 (en) | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | |
| US11795172B2 (en) | Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors | |
| AU2019350717B2 (en) | Aminopyrimidine compound | |
| US12528816B2 (en) | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | |
| HK40043646B (en) | Heterocyclic compound | |
| HK40043646A (en) | Heterocyclic compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |